Reaction
Pneumonia Legionella reporting signals
As of the last recalculation, Pneumonia Legionella appears in 1,575 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 23.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alemtuzumab | 34 | 23.7 | 23.8 |
| Infliximab | 264 | 19.0 | 19.0 |
| Rifampicin | 13 | 17.1 | 17.1 |
| Adalimumab-Fkjp | 57 | 16.8 | 16.9 |
| Adalimumab-Aaty | 55 | 15.9 | 15.9 |
| Baricitinib | 11 | 15.2 | 15.2 |
| Adalimumab-Adaz | 58 | 15.0 | 15.1 |
| Mycophenilic Acid | 21 | 13.6 | 13.6 |
| Levofloxacin | 53 | 12.0 | 12.0 |
| Levofloxacin In 5% Dextrose | 53 | 12.0 | 12.0 |
| Piperacillin And Tazobactam | 11 | 11.4 | 11.4 |
| Mycophenolic Acid | 26 | 10.9 | 10.9 |
| Voriconazole Injection | 17 | 10.4 | 10.5 |
| Piperacillin Sodium And Tazobactam Sodium | 15 | 10.2 | 10.2 |
| Rifampin | 11 | 10.0 | 10.0 |
| Piperacillin Sodium,Tazobactam Sodium | 19 | 9.6 | 9.6 |
| Voriconazole | 21 | 9.2 | 9.3 |
| Pegaspargase | 8 | 8.7 | 8.7 |
| Daratumumab | 23 | 7.7 | 7.7 |
| Sorafenib | 11 | 7.0 | 7.0 |
| Thiotepa | 5 | 6.9 | 6.9 |
| Ixazomib | 14 | 6.5 | 6.5 |
| Tofacitinib Citrate | 6 | 6.1 | 6.1 |
| Durvalumab | 9 | 5.9 | 5.9 |
| Golimumab | 33 | 5.2 | 5.2 |
| Lenalidomide | 98 | 3.2 | 3.2 |
| Pomalidomide | 22 | 2.9 | 2.9 |